Sprouts Farmers Market closes $600 million revolving credit facility
Karthik Kuppusamy, Senior Vice President of Clinical Solutions at Quest Diagnostics Inc. (NYSE:DGX), a prominent healthcare provider with an $18.3 billion market cap, recently executed a sale of company stock valued at $434,350. The transaction, which took place on April 2, involved the disposal of 2,555 shares at $170 each. Following this sale, Kuppusamy retains direct ownership of 10,575 shares. According to InvestingPro data, Quest Diagnostics generally trades with low price volatility, suggesting stable market performance.
The sale was conducted under a Rule 10b5-1 sales plan, a pre-arranged trading plan that allows insiders to sell a predetermined number of shares at a predetermined time. Additionally, Kuppusamy holds indirect ownership of 358 shares through a trust and 1,613 shares in a 401(k) plan, as reported by the plan administrator. For comprehensive analysis of Quest Diagnostics’ insider trading patterns and 8+ additional exclusive insights, check out the detailed Pro Research Report available on InvestingPro.
In other recent news, Quest Diagnostics has introduced a new FDA-cleared HPV self-collection service to improve access to cervical cancer screening. This initiative aims to provide a discreet option for women, supplementing traditional methods while being available at Quest’s 2,000 patient service centers in the U.S. Quest Diagnostics also reaffirmed its full-year 2025 guidance, projecting net revenues between $10.70 billion and $10.85 billion and adjusted diluted EPS ranging from $9.55 to $9.80. However, the company expects a first-quarter revenue headwind of approximately $25 million due to adverse weather conditions. Analyst firm Redburn-Atlantic has initiated a Buy rating on Quest Diagnostics, citing potential for steady growth and a $195 price target. Meanwhile, Truist Securities has maintained a Hold rating with a $182 target, recognizing the company’s scale and growth opportunities but leaving financial estimates unchanged. Quest’s strategic initiatives include investments in automation and AI, aiming for a 4-5% revenue CAGR and a 7-9% EPS CAGR beyond 2025. Despite these plans, some investors were underwhelmed by the long-term guidance, leading to mixed reactions from analysts and a cautious market response.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.